Dabigatran etexilate API Manufacturers

Looking for Dabigatran etexilate API 211915-06-9?

Description:

Here you will find a list of producers, manufacturers and traders of Dabigatran etexilate. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Dabigatran etexilate 

Synonyms:

Dabigatran  

Cas Number:

211915-06-9 

DrugBank number:

DB06695 

Unique Ingredient Identifier:

2E18WX195X

Dabigatran etexilate is a type of Direct thrombin inhibitors

Direct thrombin inhibitors are a crucial subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) that play a vital role in anticoagulation therapy. These inhibitors are specifically designed to target and inhibit the activity of thrombin, a key enzyme involved in the blood clotting process.

Thrombin is responsible for converting fibrinogen into fibrin, the insoluble protein that forms the backbone of blood clots. By directly inhibiting thrombin, these APIs prevent the formation of blood clots, making them highly effective in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and stroke.

Direct thrombin inhibitors offer several advantages over traditional anticoagulants. Unlike heparin and warfarin, which target multiple coagulation factors, these inhibitors act specifically on thrombin, leading to a more predictable anticoagulant effect. Moreover, they have a rapid onset of action and do not require routine monitoring or frequent dosage adjustments.

Some commonly used direct thrombin inhibitors include dabigatran, argatroban, and bivalirudin. These APIs are typically administered orally or intravenously, depending on the specific clinical scenario. However, it is crucial to note that the use of direct thrombin inhibitors requires careful patient selection and monitoring, as they may increase the risk of bleeding.

In conclusion, direct thrombin inhibitors represent an important subcategory of pharmaceutical APIs that provide targeted and effective anticoagulation therapy. Their specific mechanism of action and favorable pharmacokinetic profiles make them valuable tools in the management of thromboembolic disorders, improving patient outcomes and reducing the risk of complications.

Dabigatran etexilate (Direct thrombin inhibitors), classified under Anticoagulants

Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.

There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.

Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.

While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.

In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.

• Vasudha Pharma Chem Ltd. from India
• Gonane Pharma from India
• Apino Pharma Co., Ltd. from China
• Solfyn International LLP from India
• Lupin from India
• Qilu Antibiotics from China
• Fabbrica Italiana Sintetici (FIS) from Italy
• Menovo from China
• Cadila Healthcare from India
• Apotex Pharmachem from India
• Teva API from Israel
• Intas Pharma from United Kingdom
• Megafine Pharma (P) Ltd. from India
• Biocon from India
• Jubilant Generics from India
• Boehringer Ingelheim from Germany
• Aurobindo from India
• Glenmark Pharma from India
• Jiangxi Synergy from China
• Alembic Pharma from India
• Optimus Drugs Pvt Ltd from India
• Piramal Pharma Solutions from India
• MSN Labs. from India
• Sun Pharma from India
• Dr. Reddy's from India
• Hetero Drugs from India
• Micro Labs from India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.